Usage and dosage
1. Unstable angina pectoris and non-ST-segment elevation myocardial infarction: 5261 pericardial 4102 injections of 120U/kg(maximum dose of 10000U), twice a day, 1653 for 5-8 days or until the condition is stable, and aspirin was taken at the same time; For patients who want to receive interventional therapy but need to be delayed, heparin sodium can be sustainably administered up to 5000U(female weight <80kg, male weight <70kg) or 7500U hypodermic injection twice a day.
2. Prevention of deep vein thrombosis after surgery: subcutaneous injection of 2500U 1 to 2 hours before surgery, subcutaneous injection of 2500U 12 hours after surgery, then 2500U, once a day for 5 to 10 days, until the patient can be active.
3. Prevent blood clotting during hemodialysis and hemofiltration: For patients with no known risk of bleeding in chronic renal failure, if hemodialysis or hemofiltration does not exceed 4 hours, 5000U can be injected intravenially. For more than 4 hours, 30 ~ 40U/kg was given intravenously, followed by 10 ~ 15U/kg per hour. (2) For acute renal failure with a high risk of bleeding, intravenous injection of 5 ~ 10U/kg. For patients undergoing hemodialysis with short treatment intervals, comprehensive monitoring of anti-XA factor should be conducted, and plasma concentration should be kept within the range of 0.2 ~ 0.4 anti-XA/mL.
4. Treatment of acute deep vein thrombosis: subcutaneous injection of 200U/kg, once a day, with the total daily amount not exceeding 18000U. For patients at higher risk of bleeding, it can also be 100U/kg, twice a day. Start oral warfarin treatment with heparin, and stop this drug when INR reaches 2.3 ~ 3.o (usually about 5 days of combined treatment).
Concurrent use of drugs that have an impact on hemostasis, such as thrombolytic drugs, acetylsalicylic acid, non-steroidal anti-inflammatory drugs, vitamin K antagonists and glucan may enhance the anticoagulant effect of heparin sodium.
However, low doses of acetylsalicylic acid may be administered orally in patients with unstable coronary artery disease such as unstable angina and non-Q-wave myocardial infarction, except in patients with specific contraindications.
Acute gastroduodenal ulcers and cerebral hemorrhage, severe clotting disorders, septic endocarditis, injuries to the central nervous system, eyes and ears or surgery, thrombocytopenia in patients with positive in vitro platelet aggregation test with heparin sodium is treated with local anesthesia for acute deep venous thrombosis.
Can cause bleeding, especially in large doses. Subcutaneous hematomas are common. Rare thrombocytopenia, skin necrosis, anaphylaxis, and hemorrhage. Transient mild to moderate elevation of hepatic transaminase has been observed, and anaphylaxis is rare.